Home / Pharmaceuticals / Levothyroxine Sodium Market By Disease Indication (Hypothyroidism, Goiter, Thyroid Cancer, Myxedema Coma) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Levothyroxine Sodium Market By Disease Indication (Hypothyroidism, Goiter, Thyroid Cancer, Myxedema Coma) - Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Published: Nov 2018 | Report Code: 59442-11-18

Industry Outlook

Hypothyroidism as a syndrome was first recognized in the 1870s and its treatment with animal extracted thyroid was achieved in 1890s. Since 1927, synthetic thyroid hormone replacement therapy has been available, and in the recent years, there has been a minor shift in treatment away from levothyroxine. The currently popular treatment forms include use of liothyronine T3 as a monotherapy or even commonly combined with levothyroxine T3/T4. However, there is not current formulation of T3/T4 that completely replicates the natural hormone pattern released from human thyroid. Levothyroxine formulations have been vastly available across the global market.

Market Synopsis

Levothyroxine Sodium Market

Get a sample copy for more information

"Hypothyroidism to occupy the Largest Revenue Share through the Forecast Period"

Hypothyroidism is the common thyroid disorder observed worldwide. Autoimmune diseases (Hashimoto thyroiditis) and iodine deficiency account for vast majority of primary hypothyroidism cases. Approximately one-third of the global population is housed in iodine deficient areas and the consequences of iodine deficiency often reflect through growth disorders and hypothyroidism. Hypothyroidism is tem times more prevalent in women than in men, whereas the prevalence of untreated overt hypothyroidism is significantly low. However, implementation of new thyroid function testing and low threshold treatment indication for thyroid disorders have resulted in growth in prescriptions of levothyroxine for hypothyroidism. In Europe, the prevalence of overt hypothyroidism ranged between 0.2% and 5.3%, which is further between 0.3% and 3.7% in the U.S.

Levothyroxine Sodium Market

Get a sample copy for more information

"Asia Pacific Set to Become a Prominent Market for Levothyroxine Sodium"

North America remains the largest market for levothyroxine sodium drugs on the global front. The American thyroid Association reports that approximately 12% of the U.S. population shall develop thyroid condition during their lifetime, and 20 million Americans have some form of thyroid condition at any given time. High prevalence of thyroid disorders, better diagnostic regimen, and smaller treatment threshold are the key factors supporting the global dominance of North America market. Additionally, better reimbursements to levothyroxine drugs regimen both for short and long term treatments drive the market growth. On the other hand, Asia Pacific will progress at faster growth rate during the forecast period from 2018 to 2026. Rapidly growing awareness and significant untapped opportunities, along with evidently large patient population contribute to the rapid progress of Asia Pacific market. China and India are the most prominent markets for levothyroxine drugs. The prevalence of subclinical hypothyroidism in China has risen to 3.22%. A large  cross-sectional multicity study in India reported high prevalence of hypothyroidism (10%).

Levothyroxine Sodium Market

Get a sample copy for more information

Levothyroxine Sodium Market

Historical & Forecast Period

This research report presents the analysis of each considered segment for the period from 2016 to 2026, having 2017 as the base year for estimations. Compounded annual growth rates (CAGRs) for each segment are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

The levothyroxine sodium market report provides a quantitative assessment of the industry terms of current and forecasted market size, while also presenting the market dynamics. This market is segmented based on disease indications, and geography.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Disease Indication (2016–2026; US$ Mn)
 • Hypothyroidism
 • Goiter
 • Thyroid Cancer
 • Myxedema Coma

 Geography Segment (2016–2026; US$ Mn)
 • North America (United States and Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

In this report, the in-trend market dynamics of the global levothyroxine sodium are studied to reflect the qualitative and quantitative information pertaining to the industry. Factors such as drivers and challenges are studied in the report to determine the prevalent market trends. Opportunities for new and existing market players are also enumerated in this report. This study also includes profiling of key market players in terms of their business overview, financial status, product offering and key developments. Some of the major players profiled in this report include Mylan Laboratories, Inc., Farmak (Farmak Group N.V.),  Goldline Laboratories, Inc., IBSA Institut Biochimique SA, Fresenius Kabi USA Llc, Piramal Critical Care Ltd.,  Cediprof, Inc., King Pharmaceuticals Research And Development Llc, Abbvie, Inc., Takeda Pharmaceutical Company Ltd., Merck KGaA, Jerome, Stevens Pharmaceuticals, Inc., Pfizer, Inc., Teva Pharmaceuticals, Abbott Laboratories, Inc., Sandoz (Novartis International AG), and Lloyd, Inc.

Key questions answered in this report

  • What is the current and future status of the global levothyroxine sodium market in terms of market size?
  • At which CAGR will the global levothyroxine sodium market progress during the forecast period from 2018 to 2026?
  • What are the major market opportunities present in the market?
  • Which are the major drivers and restraints shaping the trends in the global levothyroxine sodium market?
  • Why is hypothyroidism the largest disease condition for levothyroxine sodium?
  • Will the prominence of North America challenged by the rapidly progressing Asia Pacific market?

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global LS Market Portraiture
2.2. Global LS Market, by Disease Indication, 2017 (US$ Mn)
2.3. Global LS Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Levothyroxine Sodium (LS) Market: Dynamics and Future Outlook
3.1. Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global LS Market, by Key Players, 2017

Chapter 4. Global Levothyroxine Sodium (LS) Market, by Disease Indication, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Hypothyroidism
4.3. Goiter
4.4. Thyroid Cancer
4.5. Myxedema Coma

Chapter 5. Global Levothyroxine Sodium (LS) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. Overview
5.1.1. North America LS Market, 2016 - 2026 (US$ Mn)
5.1.2. North America LS Market, by Disease Indication, 2016 - 2026 (US$ Mn)
5.1.3. North America LS Market, by Country, 2016 – 2026 (US$ Mn)
5.1.3.1. U.S.
5.1.3.2. Canada
5.2. Europe LS Market, 2016 – 2026 (US$ Mn)
5.2.1. Europe LS Market, by Disease Indication, 2016 - 2026 (US$ Mn)
5.2.2. Europe LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific LS Market, 2016 – 2026 (US$ Mn)
5.3.1. Asia Pacific LS Market, by Disease Indication, 2016 - 2026 (US$ Mn)
5.3.2. Asia Pacific LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America LS Market, 2016 – 2026 (US$ Mn)
5.4.1. Latin America LS Market, by Disease Indication, 2016 - 2026 (US$ Mn)
5.4.2. Latin America LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa LS Market, 2016 – 2026 (US$ Mn)
5.5.1. Middle East & Africa LS Market, by Disease Indication, 2016 - 2026 (US$ Mn)
5.5.2. Middle East & Africa LS Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa

Chapter 6. Company Profiles
6.1. Mylan Laboratories, Inc.
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. Key Developments
6.2. Farmak (Farmak Group N.V.)
6.3. Goldline Laboratories, Inc.
6.4. IBSA Institut Biochimique SA
6.5. Fresenius Kabi USA Llc
6.6. Piramal Critical Care Ltd.
6.7. Cediprof Inc
6.8. King Pharmaceuticals Research And Development Llc
6.9. Abbvie, Inc.
6.10. Takeda Pharmaceutical Company Ltd.
6.11. Merck KGaA
6.12. Jerome Stevens Pharmaceuticals, Inc.
6.13. Pfizer, Inc.
6.14. Teva Pharmaceuticals
6.15. Abbott Laboratories, Inc.
6.16. Sandoz (Novartis International AG)
6.17. Lloyd, Inc.

* LS - Levothyroxine Sodium

FIG 1. Levothyroxine Sodium (LS) Market: Research Methodology
FIG 2. LS Market Segmentation
FIG 3. Global LS Market, by Disease Indication, 2017 (US$ Mn)
FIG 4. Global LS Market, by Geography, 2017 (US$ Mn)
FIG 5. Attractive Investment Proposition, by Geography, 2017
FIG 6. Competitive Analysis: Global LS Market, by Key Players, 2017
FIG 7. Global LS Market for Hypothyroidism Treatment, 2016 - 2026 (US$ Mn)
FIG 8. Global LS Market for Goiter Treatment, 2016 - 2026 (US$ Mn)
FIG 9. Global LS Market for Thyroid Cancer Treatment, 2016 - 2026 (US$ Mn)
FIG 10. Global LS Market for Myxedema Coma, 2016 - 2026 (US$ Mn)
FIG 11. U.S. LS Market, 2016 - 2026 (US$ Mn)
FIG 12. Canada LS Market, 2016 - 2026 (US$ Mn)
FIG 13. U.K. LS Market, 2016 - 2026 (US$ Mn)
FIG 14. Germany LS Market, 2016 - 2026 (US$ Mn)
FIG 15. Rest of Europe LS Market, 2016 - 2026 (US$ Mn)
FIG 16. China LS Market, 2016 - 2026 (US$ Mn)
FIG 17. Japan LS Market, 2016 - 2026 (US$ Mn)
FIG 18. India LS Market, 2016 - 2026 (US$ Mn)
FIG 19. Rest of Asia Pacific LS Market, 2016 - 2026 (US$ Mn)
FIG 20. Brazil LS Market, 2016 - 2026 (US$ Mn)
FIG 21. Mexico LS Market, 2016 - 2026 (US$ Mn)
FIG 22. Rest of Latin America LS Market, 2016 - 2026 (US$ Mn)
FIG 23. GCC LS Market, 2016 - 2026 (US$ Mn)
FIG 24. Rest of Middle East and Africa LS Market, 2016 - 2026 (US$ Mn)

TABLE 1 Global Levothyroxine Sodium (LS) Market Portraiture
TABLE 2 Global LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 3 Global LS Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 4 North America LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 5 North America LS Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 6 Europe LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 7 Europe LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 8 Asia Pacific LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 9 Asia Pacific LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Latin America LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 11 Latin America LS Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Middle East and Africa LS Market, by Disease Indication, 2016 – 2026 (US$ Mn)
TABLE 13 Middle East and Africa LS Market, by Region, 2016 – 2026 (US$ Mn)
TABLE 14 Mylan Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 15 Farmak (Farmak Group N.V.): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 16 Goldline Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 17 IBSA Institut Biochemique SA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 18 Fresenius Kabi USA Llc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 19 Piramal Critical Care Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 20 King Pharmaceuticals Research and Development Llc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Takeda Pharmaceutical Company Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Merck KGaA: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Jerome Stevens Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Teva Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Abbott Laboratories, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Sandoz (Novertis International AG): Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Lloyd, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
Connect With Us
+1-800-361-8290
24/7 Research Support

Our Clients